FDA 483 - Changzhou Ruiming Pharmaceuticals Co. Ltd. - September 13, 2018
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of CHANGZHOU RUIMING PHARMACEUTICAL CO LTD revealed significant deficiencies in laboratory systems and equipment qualification. Issues included unavailable electronic records for QC testing, inadequate procedures for reviewing laboratory data and media suitability testing, and deficiencies in performance qualification and calibration of production equipment. These observations indicate a lack of control over critical manufacturing and quality control processes for active pharmaceutical ingredients.
ID · 49fe08e0-6ee1-4197-96c8-be537f4a92f9